Dated: February 15, 2001.

Karl J. Sandstrom,

Commissioner, Federal Election Commission.

[FR Doc. 01–4246 Filed 2–20–01; 8:45 am]

BILLING CODE 6715–01–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than March 6, 2001.

A. Federal Reserve Bank of Kansas City (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198–0001:

1. David Jackson Swearingen and Susan Gail Swearingen, Nevada, Missouri; to acquire voting shares of 1889 Bancshares, Inc., Nevada, Missouri, and thereby indirectly acquire voting shares of First National Bank of Nevada, Nevada, Missouri.

Board of Governors of the Federal Reserve System, February 14, 2001.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 01–4172 Filed 2–20–01; 8:45 am]

BILLING CODE 6210–01–P

BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM

Government in the Sunshine; Meeting Notice

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11 a.m., Monday, February 26, 2001.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at *http://www.federalreserve.gov* for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: February 16, 2001.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 01–4447 Filed 2–16–01; 5:04 pm]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Meeting of the Advisory Committee on Blood Safety and Availability

AGENCY: Office of the Secretary, HHS.

ACTION: Notice of meeting.

The Advisory Committee on Blood Safety and Availability will meet on Thursday April 19, 2001 and Friday April 20, 2001 from 8 a.m. to 5 p.m. The meeting will take place at the Hyatt Regency Hotel on Capitol Hill, 400 New Jersey Ave., NW., Washington, DC 20001. The meeting will be entirely open to the public.

The first item on the agenda will be what should be the Department's current and future actions under its Blood Action Plan to monitor the availability of blood products in the United States. Specific comment will be solicited on what parameters should be monitored, how these parameters should be analyzed, and where responsibility for this activity should rest.

The second item on the agenda will be what, if any, actions the Department of Health and Human Services should take to strengthen current efforts to promote blood safety and availability throughout the world.

Public comment will be solicited at the meeting. Public comment will be limited to five minutes per speaker. Those who wish to have printed material distributed to Advisory Committee members should submit thirty (30) copies to the Executive Secretary prior to close of business April 5, 2001. In addition, anyone planning to comment on either item is encouraged to contact the Executive Secretary at his/her earliest convenience.

FOR FURTHER INFORMATION CONTACT: Stephen D. Nightingale, M.D., Executive Secretary, Advisory Committee on Blood Safety and Availability, Department of Health and Human Services, Office of Public Health and Science, 200 Independence Ave., SW., Room 736–E, Washington, DC 20201. Phone (202) 690–5560. FAX (202) 690–7560, e-mail *StephenDNightingale@osophs.dhhs.gov.*

Dated: February 13, 2001.

Stephen D. Nightingale,

Executive Secretary Advisory Committee on Blood Safety and Availability.

[FR Doc. 01–4243 Filed 2–20–01; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

PHS Policy on Instruction in the Responsible Conduct of Research

AGENCY: Office of the Secretary, HHS.

ACTION: Notice of suspension of ''PHS Policy on Instruction in the Responsible Conduct of Research.''

SUMMARY: On December 7, 2000, the Office of Research Integrity (ORI), in collaboration with each of the Public Health Service (PHS) Operating Divisions, announced in the **Federal Register** the issuance of a Final Policy on Instruction in the Responsible Conduct of Research. 65 FR 76647. A Draft PHS Policy on Instruction in the Responsible Conduct of Research was announced in the **Federal Register** on July 21, 2000, and made available for public comment until September 21, 2000. In response to the public comment, ORI and the PHS agencies made substantial revisions to the draft policy before its issuance in final form.

Consistent with the President's January 20, 2001, Regulatory Review Plan, on behalf of PHS, ORI hereby suspends implementation of the ''PHS Policy on Instruction in the Responsible Conduct of Research'' to permit additional review both of the substance of the policy and the process for adoption. Pending completion of that

review, institutions that might otherwise be subject to the RCR policy are under no obligation to implement the policy unless further public notice is issued in the **Federal Register**. Any future PHS action taken to implement the RCR policy would provide extended implementation time frames that take into consideration this suspension.

FOR FURTHER INFORMATION CONTACT: Barbara Bullman, J.D., Senior Program Analyst, Division of Education and Integrity, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5300.

Chris B. Pascal, J.D.,

Director, Office of Research Integrity.

[FR Doc. 01–4226 Filed 2–20–01; 8:45 am]

BILLING CODE 4150–31–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Projects

Title: TANF High Performance Bonus Report, Assessment of Medicaid and SCHIP Enrollment.

OMB No.: New Collection.

Description: Public Law 104–93 (PRWORA) established the Temporary Assistance for Needy Families (TANF) Program. It also included provisions for rewarding States that attain the highest levels of success in achieving the legislative goals of that program. The purpose of this collection is to obtain data upon which to base the computation for measuring State performance in meeting those goals by providing Medicaid and SCHIP work supports. DHHS will use the information to allocate the Medicaid/SCHIP portion of the bonus grant funds appropriated under the law and implemented by 45 CFR part 270 published on August 30, 2000. States will not be required to submit this information unless they elect to compete in a Medicaid/SCHIP measure for the TANF High Performance Bonus awards in Federal fiscal years 2002 or 2003, or any subsequent Federal fiscal year for which Congress authorizes and appropriates bonus funds.

Respondents: Respondents may include any of the 50 States, the District of Columbia, and the U.S. Territories of Guam, Puerto Rico, and the Virgin Islands.

ANNUAL BURDEN ESTIMATES

Instrument	No. of respondents	No. of responses per respondent	Average burden hours per response	Total burden hours
TANF high performance bonus report, assessment of Medicaid and SCHIP enrollment among individuals after leaving TANF assistance	54	2	40	4,320
Estimated total annual burden hours				4,320

In compliance with the requirements of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: February 14, 2001.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 01–4188 Filed 2–20–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Allergenic Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Allergenic Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on March 5, 2001, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact: William Freas or Pearline K. Muckelvene, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12388. Please call the Information Line for up-to-date information on this meeting.

Agenda: On March 5, 2001, the committee will hear updates on: (1) The Laboratory of Immunobiochemistry personnel, (2) lot release statistics, (3) new guidance documents, (4) research and standardization programs, and (5) a compliance report. The committee will discuss whether master seed stocks of mold strains used for allergenic extracts should be rederived to reduce a theoretical risk of transmissible spongiform encephalopathy transmission. The committee will also discuss the statistical power of clinical studies used to assess bioequivalence as it applies to allergen extract studies. In the afternoon, the committee will discuss particulates that appear in allergen extracts and the effect of these particulates on the safety and efficacy on these products. In closed session, the committee will receive a report on the status of an investigational new drug application and product license application supplement.

Procedure: On March 5, 2001, from 8:30 a.m. to 3:30 p.m., the meeting is open to the